Lotte Biologics, Excellgene to collaborate on CDO biz

S.Korean pharma, Swiss-based bio company will jointly build cell line’s supply chain

Lotte Biologics, Excellgene to collaborate on CDO biz
Ji-Hyun Lee 1
2023-04-03 15:18:36 bluesky@hankyung.com
Bio & Pharma

Lotte Biologics, South Korea's biopharmaceutical contract development and manufacturing organization (CDMO) company, announced on Sunday that it has entered into a memorandum of understanding (MOU) with Swiss-based cell line development company Excellgene for collaboration on contract development organization (CDO) services.

Excellgene provides cell line development services to global pharmaceutical companies and will join forces with Lotte Biologics to offer a comprehensive range of services, from cell line development to large-scale contract manufacturing of pharmaceutical cell lines.

Under the agreement, Excellgene will be responsible for cell line and high-yield process development, while Lotte Biologics will provide cell bank services and manufacture clinical and commercial pharmaceuticals.

"Enhancing CDO capabilities requires significant time and specialized personnel, but it is crucial for us to become a global CDMO company," said Lee Dong-wook, CEO of Lotte Biologics. "Through our partnership with Excellgene, which has vast experience working with leading global firms, we aim to boost not just our CMO, but also our CDO competitiveness."

Write to Ji-Hyun Lee at bluesky@hankyung.com
#Lotte Biologics #biopharmaceutical #CDMO #Excellgene #Swiss #cell line #CDO

Samsung Biologics to invest $762 mn for 5th CDMO factory

Samsung Biologics to invest $762 mn for 5th CDMO factory

Samsung Biologics headquarters in Incheon, South Korea (Courtesy of Samsung Biologics) Samsung Biologics Co. is slated to inject 1 trillion won ($762.2 million) to build its fifth plant in South Korea. It will be a fast follow-up investment as the construction of its fourth plant, the world's l

Daewoong accelerates investment in CDMO business

Daewoong accelerates investment in CDMO business

Daewoong Bio Laboratory Daewoong, the holding company of South Korea's pharmaceutical-oriented Daewoong Group, is speeding up its pace to beef up its contract development and manufacturing (CDMO) business.In its stock exchange filing on Monday, Daewoong revealed that its subsidiary Daewoong Bio

Medipost acquires Canada’s OmniaBio for CDMO business

Medipost acquires Canada’s OmniaBio for CDMO business

Medipost headquarters building Medipost Co., a South Korean biotechnology company, has acquired a 39.6% stake in OmniaBio Inc., a Canada-based cell and gene therapy contract development and manufacturing organization (CDMO) firm, for 29.5 billion won, or C$30 million.The stake purchase is aimed

K-bio firms embrace gene therapy CDMO as Samsung looks the other way

K-bio firms embrace gene therapy CDMO as Samsung looks the other way

South Korea's first homegrown COVID-19 vaccine, SKYCovione, produced by SK Bioscience South Korea’s major biopharmaceutical companies are rapidly embracing the cell and gene therapy business under a contract drug-making mechanism while Samsung Biologics Co. remains lukewarm toward the eme
(* comment hide *}